Markets:

Overview

News

Currencies

International

Treasuries

Novartis AG Common Stock (NY:NVS)

127.31 +2.95 (+2.37%)

Official Closing Price Updated: 7:00 PM EST, Nov 21, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

52 53 Next >

Arrowhead Pharma Jumps After Inking A Deal Worth Up To $2.2 Billion ↗

September 02, 2025

Arrowhead Pharmaceuticals and Novartis inked a licensing deal Tuesday for an experimental Parkinson's drug.

Via Investor's Business Daily

Gateway to Growth: Innovation and Opportunity at the 8th CIIE

September 01, 2025

Via Press Release Distribution Service

Topics Economy

Gateway to Growth: Innovation and Opportunity at the 8th CIIE

September 01, 2025

Via Get News

Topics Economy

Novo Nordisk Slowdown Weighs On Denmark's Economic Outlook ↗

August 29, 2025

Novo Nordisk alone contributing one-fifth of employment gains to Denmark. But economic headwinds are mounting.

Via Benzinga

How Is The Market Feeling About Novartis? ↗

August 15, 2025

Via Benzinga

P/E Ratio Insights for Novartis ↗

August 12, 2025

Via Benzinga

Novartis Rides Bullish Retail Mood, Roche Faces Gloom Amid Swiss-US Trade Concerns ↗

August 11, 2025

Via Stocktwits

Novartis Reportedly Eyeing To Acquire Avidity Biosciences: But Retail Expects Management To Sell Only At Significant Premium ↗

August 06, 2025

Via Stocktwits

Global Trade Braces for Impact: US-China Tariff Tensions Persist Amidst Fleeting Truces and Escalating Duties

August 28, 2025

The global economic landscape remains deeply entrenched in a complex and often volatile trade conflict between the United States and China. What began in January 2018 as a series of targeted duties has...

Via MarketMinute

Topics Artificial Intelligence Economy Government

FDA Eases Monitoring Burden For Kidney Disease Patients On Travere Therapeutics' Filspari ↗

August 28, 2025

FDA eases REMS labeling for Travere's Filspari, reducing liver monitoring and removing embryo-fetal toxicity rules, with FSGS approval review ongoing.

Via Benzinga

Powering Progress: AI's Insatiable Energy Appetite and Biotech's Dual Dawn

August 27, 2025

The global economy in 2025 is navigating a landscape profoundly reshaped by the escalating demands of Artificial Intelligence (AI) and transformative shifts in healthcare. While the burgeoning energy...

Via MarketMinute

Topics Artificial Intelligence Economy Emissions

UK Drug Pricing Talks Collapse, Drugmakers Reject Offer Citing 'Uncompetitive' System ↗

August 22, 2025

UK drug pricing talks collapsed after the government and pharma firms failed to agree on National Health Service rebates.

Via Benzinga

Novartis AG-Sponsored ADR (NYSE:NVS) – A Top Dividend Stock with Strong Yield and Financial Stability ↗

August 18, 2025

Novartis (NVS) offers a strong 3.55% dividend yield, backed by consistent payouts, solid profitability, and financial health—ideal for stable income investing.

Via Chartmill

Massive Headwinds Are on the Horizon for Pharmaceutical Stocks, but Here Are 2 That Could Weather the Storm ↗

August 17, 2025

These companies have successfully navigated similar obstacles before.

Via The Motley Fool

Topics Intellectual Property

2 Dividend Stocks to Buy and Hold ↗

August 15, 2025

These stocks look like they can weather almost any storm.

Via The Motley Fool

Topics Artificial Intelligence Cannabis Government

NOVARTIS AG-SPONSORED ADR (NYSE:NVS) Emerges as a Top Pick for Value Investors with Strong Fundamentals and Attractive Valuation ↗

August 15, 2025

Novartis AG-SPONSORED ADR (NVS) is a top pick for value investors, offering solid fundamentals, strong profitability, and a 3.76% dividend yield, all at an attractive valuation.

Via Chartmill

Vor Bio Rallies On Strong Data For Autoimmune Drug Candidate ↗

August 13, 2025

Vor Bio shares climb as RemeGen's Phase 3 study in China shows telitacicept improves disease activity in primary Sjögren's disease.

Via Benzinga

Novartis Sees Hope In Reducing Lifelong Treatment Burden For Autoimmune Blood Disorder ↗

August 12, 2025

Novartis' ianalumab plus eltrombopag significantly extended treatment response and improved platelet counts in a Phase 3 immune thrombocytopenia trial.

Via Benzinga

This Stock Has Tumbled 50% In One Year, Gets A Price Target Cut Today – But Retail Believes $400-450 Is A Good Entry Point ↗

August 11, 2025

Truist, however, kept a ‘Buy’ rating on the shares.

Via Stocktwits

Novartis Drug Shows Improvement In Sjögren's Disease In Late-Stage Trials: Analyst Deems Data Positive For Zura Bio As Well ↗

August 11, 2025

Novartis now sees the potential for the drug to become the first and only targeted treatment approved for patients with the disease.

Via Stocktwits

Novartis' Investigational Drug Aces Two Pivotal Trials For Chronic Disease Impacting Tears, Saliva ↗

August 11, 2025

Novartis' ianalumab showed significant disease activity improvement in two Phase 3 Sjögren's trials, supporting plans for global health authority filings.

Via Benzinga

Genmab/AbbVie Partnered Blood Cancer Combination Drug Cuts Risk Of Disease Progression By 79% ↗

August 08, 2025

Genmab reported strong Phase 3 trial results for epcoritamab in FL, secured FDA priority review, and raised its 2025 sales outlook after Q2 beat.

Via Benzinga

2 Brilliant Vanguard Index Funds to Buy With $1,000 in August and Hold Forever ↗

August 08, 2025

These Vanguard index funds offer diversified exposure to many of the most influential stocks in the world.

Via The Motley Fool

Topics ETFs

PTCT Earnings Beat but Sales Drop 4% ↗

August 07, 2025

Via The Motley Fool

Topics Earnings

Monte Rosa (GLUE) Q2 Revenue Jumps 394% ↗

August 07, 2025

Via The Motley Fool

Topics Artificial Intelligence Intellectual Property

Schrödinger (SDGR) Q2 2025 Earnings Transcript ↗

August 06, 2025

Via The Motley Fool

Novo Nordisk Commits To Advancing Prothena Corp-Developed Drug Into Late Stage Trial: Retail Turns Hopeful ↗

August 06, 2025

Coramitug was initially developed by Prothena and was acquired by Novo Nordisk in July 2021.

Via Stocktwits

Topics Earnings

Avidity Biosciences Rockets As Novartis Reportedly Mulls A Takeover Deal ↗

August 06, 2025

The company is focused on treatments for forms of muscular dystrophy.

Via Investor's Business Daily

Pfizer's Ascent Signals Broader Health Sector Resilience Amidst Innovation Wave

August 04, 2025

In a notable shift, shares of Pfizer (NYSE: PFE) have recently edged higher, reflecting a burgeoning strength within the broader health sector. This uptick signals a renewed investor confidence in the...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

Trump Turns Up Heat On Big Pharma CEOs To Slash Drug Prices Within 60 Days — But Retail Traders Don't Flinch ↗

July 31, 2025

Via Stocktwits

Topics Government

< Previous 1 2 3 4 5 6 7 8 9

...

52 53 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Novartis AG Common Stock (NY:NVS)

All News about Novartis AG Common Stock

Starting at $3.75/week.

Subscribe Today